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In biology, thrombosis is a mechanism of
maintaining the integrity of biological sur-
faces in higher mammals, limiting fluid
loss, and facilitating the recognition, con-
tainment, and destruction of pathogens
and foreign materials by a scaffold of fib-
rin and DNA strands. However, thrombosis
may also lead to vascular occlusion and
subsequent tissue damage.
In medicine, thrombosis is a hall-
mark of life-threatening cardiovascular
diseases, such as myocardial infarction,
stroke, or venous thromboembolism repre-
senting major causes of death in the West-
ern civilization. Every year 17 million indi-
viduals die from cardiovascular disease (1,
2), comprising almost half of the global
death toll in Europe. For example, in Aus-
tria, 34,000 patients suffered a cardiovascu-
lar death in 2012, accounting for 42.7% of
all deaths, which is 1.7-fold the death toll
of malignant diseases (3).
Cardiovascular science beyond clini-
cal observation and anatomical dissection
emerged in the late 19th and early 20th
centuries. A key observation was the epi-
demiological connection of hypertension
and elevated plasma lipids with athero-
sclerotic vascular disease (4). Based on a
more profound understanding of these risk
factors, including exercise, body weight,
and glucose metabolism, preventive mea-
sures were tested, leading to both pri-
mary and secondary preventions that have
become powerful modulators of disease
decreasing events by almost half. Since
then, the establishment of coronary care
units, cardiac catheterization, angioplasty,
and surgery and the advent of modern
medications many of which interfere with
thrombosis and platelet aggregation, have
contributed to fundamental improvements
in cardiovascular care. However, much of
the advances in cardiovascular science have
been in the thrombosis field, stimulated
by the discovery that myocardial infarc-
tion was due to thrombi in the coronary
arteries (5). Traditionally, thrombosis has
been viewed as the biochemical result of
regulated cascades of protein interactions
characterized by the activation of factor
X and the activation of thrombin, result-
ing in the formation of fibrin. Accord-
ingly, treatments for myocardial infarction,
stroke, and venous thromboembolism have
targeted pathways or more recently, indi-
vidual protein moieties (Figure 1). Table 1
summarizes landmark trials leading to the
approval of individual compounds. Over
50 years, a plethora of treatments has been
brought to market (Table 1), with high
efficacy and safety profiles that have con-
tributed to the observation that death rates
per 100,000 population were decreased
from 450 in the 1950s to 150 around 2010
(6). For example, while 20–30% of hospi-
talized patients with myocardial infarction
died within 30 days due to their underlying
disease, this number has been substantially
decreased to <5% most recently (7).
The public domain is thrilled with
advances of cardiovascular medicine, and
needs for deeper insights are hardly con-
vincing in an environment of harmonized
health care providing infarction networks,
stent-for-life programs, and generally high
standard guidelines in cardiovascular care.
However, do we understand throm-
bosis, do we understand recurrence, or
do we prefer, for example, to mandate
life-long factor X inhibition (38, 46–48)
and statins (49) in patients at risk, with-
out further investigation of underlying
mechanisms?
More recently, a new view of thrombo-
sis has emerged accounting for thrombosis
as a vascular disease involving the dynamic
interaction between platelets, circulating
inflammatory cells, nucleic acids and pro-
teins, and resident cells of the vascular wall.
Milestones along the way of integrating the
vessel wall in the thrombotic process were
the discovery and action of nitric oxide (50,
51), the delineation of the LDL-cholesterol
pathway (52, 53), the role of soluble and
membrane bound tissue factor in athero-
sclerosis (54), and most recently the con-
cept of “immunothrombosis” (55), linking
inflammation and thrombosis as regula-
tors of vascular integrity. Consequently,
it was understood that the hemostatic
system is a modulator of atherosclerosis
(56). Thrombosis comprises both acute
clotting and the more time-consuming
process of thrombus resolution, which
represents a vascular remodeling process
that is driven by inflammation, angio-
genesis, and cells of the innate immune
system. A stimulus leading to throm-
bus formation induces an innate immune
response that is supported by neutrophils,
lymphocytes, macrophages, by specific
thrombosis-related molecules, and neu-
trophil extracellular traps (NETS), under-
pinning the importance of the following
questions:
Is thrombosis the underlying process
behind both arterial and venous dis-
ease that oftentimes combines in indi-
vidual patients? (57) Do we understand
endothelial dysfunction, and is it the
nidus for thrombosis, and eventually vas-
cular occlusion? And why do acute pul-
monary emboli transform into chronic
vascular obstructions in chronic throm-
boembolic pulmonary hypertension? Do
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FIGURE 1 | Process of coagulation and the primary sites of action of current pharmacologic agents.
Table 1 | Overview of treatments approved for vascular thrombosis (antithrombotics, comprising thrombolytics, anticoagulants, and
antiplatelet drugs).
Concept Mechanism of
action
Compound
(key reference)
Indication Benefits/Harms
Antiplatelet
drugs
COX inhibition Acetylsalicylic
acid/Aspirin (8)
Prevention of cardiovascular events Increased risk of bleeding when
combined with NSAIDs
ADP receptor/
P2Y12 inhibition
Clopidogrel (9) Prevention of thrombotic events Pro-drug limited by metabolization,
irreversible
Clopidogrel (10) ACS Pro-drug limited by metabolization,
irreversible
Prasugrel (11, 12) Prevention of thrombotic events Rapid onset of action, high efficacy,
particularly in diabetic subjects,
increased bleeding rates in those aged
>75 years, and in those with previous
stroke and a weight less than 60 kg,
irreversible
Ticagrelor (13) Prevention of thrombotic events
particularly in STE-ACS
Rapid onset of action, reversible, high
efficacy, low bleeding rates, provides a
survival benefit in ACS
Phosphodiesterase
inhibition
Cilostazol (14) Reduction of symptoms of intermittent
claudication
Phosphodiesterase 3 inhibitor,
potentially dangerous in severe heart
failure
Glycoprotein
IIb/IIIa inhibition
Abciximab (15, 16) For use in individuals undergoing PCI with
or without stent placement to decrease
the incidence of ischemic complications
due to the procedure
Effective prevention of ischemic
events, particularly in diabetic subjects,
and subjects with chronic kidney
disease, increased bleeding rates only
in high-risk patients
(Continued)
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Table 1 | Continued
Concept Mechanism of
action
Compound
(key reference)
Indication Benefits/Harms
Tirofiban (17) Reduction of the rate of thrombotic
cardiovascular events (combined endpoint
of death, myocardial infarction, or
refractory ischemia/repeat cardiac
procedure) in patients with NSTE-ACS
Rapid onset and short duration of
action (4–8 h)
Eptifibatide (18) Reduction of the risk of acute cardiac
ischemic events (death and/or myocardial
infarction) in patients with UA or
NSTE-ACS both in patients who are to
receive medical treatment and those
undergoing PCI
Short half-life
Anticoagulants Vitamin K
antagonism
Vitamin K antagonists
(19)
Prevention and treatment of venous
thromboembolism, atrial fibrillation,
mechanical and bioprosthetic heart valves,
post-myocardial infarction, recurrent
systemic embolism and other indications
Accepted standard, reproducible
results, high exposure rates, cheap, no
contraindication in patients with GFR
<30 mL/min
Factor Xa
inhibition
Unfractionated heparin
(20–23) new ESC
Guidelines pending
2014
Deep vein thrombosis (DVT) in patients
with renal failure
HIT possible
Low-molecular weight
heparins, e.g.,
enoxaparin (23, 24)
Prevention of DVT in hip or knee
replacement surgery, or in abdominal
surgery or acutely ill patients with
severely restricted mobility at risk for
thromboembolism
Accumulates in chronic renal failure
Low-molecular weight
heparins, e.g.,
enoxaparin (25, 26)
Prevention of ischemic complications of
UA and NSTE-ACS. STE-ACS managed
medically or with subsequent PCI
Accumulates in chronic renal failure
Low-molecular weight
heparins, e.g.,
enoxaparin (27)
Acute pulmonary embolism Accumulates in chronic renal failure
Fondaparinux (28) ACS Positive effect on survival, thrombus
formation on wires/balloons during
(primary) PCI if no additional heparin is
used, contraindicated in severe renal
failure with a GFR <20 mL/min
Fondaparinux (29) Prophylaxis of DVT in patients undergoing
hip facture surgery, hip replacement
surgery and knee replacement surgery.
50% VTE risk reduction compared with
enoxaparin, no increase in clinically
relevant bleeding Contraindicated in
severe renal failure with a GFR
<20 mL/min
Rivaroxaban (30) VTE prophylaxis Easy administration, once daily, more
effective compared with enoxaparin,
same safety profile
Rivaroxaban (31) Non-valvular atrial fibrillation Non-inferior to warfarin for the
prevention of stroke or systemic
embolism, same risk of major bleeding,
however, less intracranial and fatal
(Continued)
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Table 1 | Continued
Concept Mechanism of
action
Compound
(key reference)
Indication Benefits/Harms
Rivaroxaban (32) Reduction of the risk of recurrent
atherothrombotic events in patients with
acute coronary syndromes
Less cardiovascular death, myocardial
infarction and stroke, but increased risk
of major bleeding and intracranial
hemorrhage, but not fatal bleeding
Apixaban (33) Non-valvular atrial fibrillation Compared with warfarin less ischemic
strokes
Apixaban (34) VTE prophylaxis Superior to enoxaparin in preventing
thrombosis
Direct thrombin
(II) inhibition
Lepirudin (35) ACS Low exposure rates, little information
Bivalirudin (36) ACS Survival benefit, however, signal of
increased early stent thrombosis
Dabigatran (37),
http://www.fda.gov/
Drugs/DrugSafety/
ucm396470.htm
Reduction of risk of stroke and systemic
embolism in Non-valvular atrial fibrillation
Compared with warfarin less
hemorrhagic strokes, mild increase of
GI bleeds, antibody-based antidote in
development
Dabigatran (38) Reduction of the risk of recurrence of DVT
and pulmonary embolism
Compared with warfarin less
hemorrhagic strokes, mild increase of
GI bleeds, antibody-based antidote in
development
Dabigatran (39) Treatment of DVT and pulmonary
embolism
Compared with warfarin less
hemorrhagic strokes, mild increase of
GI bleeds, antibody-based antidote in
development
Argatroban (40) Prophylaxis or treatment of thrombosis in
patients with heparin-induced
thrombocytopenia; including patients
undergoing PCI
Low exposure rates, low case numbers
Thrombolytic
drugs/
fibrinolytics
Streptokinase (41) Acute pulmonary embolism Relatively low fibrin specificity,
inexpensive
Streptokinase (42) Acute coronary syndrome Relatively low fibrin specificity,
inexpensive
Alteplase (43) Acute ischemic stroke Recombinant tissue-type plasminogen
activator with improved fibrin binding
Reteplase (44) Acute coronary syndrome longer half-life, better penetration into
thrombus
Tenecteplase (45) Reduction of mortality associated with
acute myocardial infarction
higher fibrin specificity and greater
resistance to inactivation by its
endogenous inhibitor (PAI-1) compared
to native t-PA
Selected references and selected indications are displayed. COX= cyclo-oxygenase, NSAID=non-steroidal anti-inflammatory drugs, kg= kilograms, ACS= acute
coronary syndrome, PCI=percutaneous coronary intervention, UA=unstable angina, STE-ACS=ST elevation acute coronary syndrome, NSTE-ACS=non-ST ele-
vation acute coronary syndrome, GFR= glomerular filtration rate, HIT=heparin-induced thrombocytopenia, ACS= acute coronary syndromes, DVT=deep venous
thrombosis, VTE= venous thromboembolism, GI=gastro-intestinal, PAI-1=plasminogen activator inhibitor type 1, t-PA= tissue-type plasminogen activator.
we understand acute vascular syndromes
simply by plaque rupture that is dri-
ven by macrophages that are loaded with
lipids, and proteolytically cleave a thin-
cap fibroatheroma thus triggering platelet
activation? Does that concept explain acute
coronary syndromes in young subjects
without significant vascular stenoses? Is
thrombosis per se the trigger for all vas-
cular occlusion, be it chronic or acute?
Is vascular occlusion the sequlae of defi-
cient efferocytosis, and are those mech-
anisms driven by a deficiency of natural
antibodies? What are the recognition sites
for natural antibodies in the circulation?
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Which cells or cell fragments in the circu-
lation are carrying oxidation specific epi-
topes, e.g., oxidized low-density lipopro-
tein (OxLDL) or malon-dialdehyde, and
how do they function as danger associ-
ated molecular patterns? What is the role of
nucleic acids, RNAse, and DNAse in throm-
bosis? Is NETting a preventable amplifier of
acute thrombosis and the adverse vascular
remodeling following thrombosis?
Are there potential therapeutic targets,
upstream of mechanisms of thrombosis
that might be applied without any poten-
tial bleeding risk? And might addressing
those new targets prevent recurrence? Will
we be able to identify a cellular program to
minimize the potential of thrombosis and
vascular occlusion? Will we be restoring
normal Ca2+ cycling and reduce reperfu-
sion injury? Will we be utilizing therapeutic
antagomirs to control cellular responses to
vascular injury? Will we be engineering ves-
sels and vascular compartments of organ
systems?
While bench-top research will address
these questions, clinical research will com-
plement advances both in drug-based tri-
als and in interventional approaches. Since
the PEITHO trial, the term of acute pul-
monary revascularization has been coined
in analogy to coronary revascularization,
leading the way to interventional treat-
ments (58) as adjunct or stand-alone
treatments for the pulmonary circula-
tion. Similar developments have recently
been initiated in chronic pulmonary vas-
cular disease and will change treatment
paradigms (59–62).
Taken together, thrombosis is an impor-
tant mediator of vascular disease, but can-
not be seen in isolation. Data suggest that
it most often occurs as the consequence
of a loss of vascular barrier function, for
example, in the context of inflammation
and rarely as a primary event. To com-
prehend mechanisms of vascular barrier
function is another challenge of throm-
bosis research of the future. To under-
stand thrombosis, we need to look beyond
thrombosis.
REFERENCES
1. Murray CJ, Lopez AD. Measuring the global bur-
den of disease. N Engl J Med (2013) 369:448–57.
doi:10.1056/NEJMra1201534
2. Laslett LJ, Alagona P Jr., Clark BA III, Drozda JP
Jr., Saldivar F, Wilson SR, et al. The worldwide
environment of cardiovascular disease: prevalence,
diagnosis, therapy, and policy issues: a report from
the American College of Cardiology. J Am Coll
Cardiol (2012) 60:S1–49. doi:10.1016/j.jacc.2012.
11.002
3. Schneider B. Statistik Austria 2012. Österreichische
Ärztezeitung (2013):doi:10.3109/02699052.2014.
904522
4. Kannel WB, Dawber TR, Kagan A, Revotskie N,
Stokes J III. Factors of risk in the development
of coronary heart disease – six year follow-up
experience. The Framingham Study. Ann Intern
Med (1961) 55:33–50. doi:10.7326/0003-4819-55-
1-33
5. Hektoen L. Embolism of the left coronary artery;
sudden death. Med Newsl (London) (1892) 61:210.
6. Nabel EG, Braunwald E. A tale of coronary artery
disease and myocardial infarction. N Engl J Med
(2012) 366:54–63. doi:10.1056/NEJMra1112570
7. Kalla K, Christ G, Karnik R, Malzer R, Norman
G, Prachar H, et al. Implementation of guide-
lines improves the standard of care: the Vien-
nese registry on reperfusion strategies in ST-
elevation myocardial infarction (Vienna STEMI
registry).Circulation (2006) 113:2398–405. doi:10.
1161/CIRCULATIONAHA.105.586198
8. Lewis HD Jr., Davis JW, Archibald DG, Steinke
WE, Smitherman TC, Doherty JE III, et al. Pro-
tective effects of aspirin against acute myocardial
infarction and death in men with unstable angina.
Results of a Veterans Administration Coopera-
tive Study. N Engl J Med (1983) 309:396–403.
doi:10.1056/NEJM198308183090703
9. Committee CS. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE). CAPRIE Steering
Committee. Lancet (1996) 348:1329–39. doi:10.
1016/S0140-6736(96)09457-3
10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni
G, Fox KK, et al. Effects of clopidogrel in addi-
tion to aspirin in patients with acute coro-
nary syndromes without ST-segment elevation.
N Engl J Med (2001) 345:494–502. doi:10.1056/
NEJMoa010746
11. Montalescot G, Wiviott SD, Braunwald E, Mur-
phy SA, Gibson CM, Mccabe CH, et al. Prasug-
rel compared with clopidogrel in patients under-
going percutaneous coronary intervention for ST-
elevation myocardial infarction (TRITON-TIMI
38): double-blind, randomised controlled trial.
Lancet (2009) 373:723–31. doi:10.1016/S0140-
6736(09)60441-4
12. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel
S, Dalby AJ, Verheugt FW, et al. Greater clinical
benefit of more intensive oral antiplatelet therapy
with prasugrel in patients with diabetes mellitus
in the trial to assess improvement in therapeutic
outcomes by optimizing platelet inhibition with
prasugrel-Thrombolysis in Myocardial Infarction
38. Circulation (2008) 118:1626–36. doi:10.1161/
CIRCULATIONAHA.108.791061
13. Wallentin L, Becker RC, Budaj A, Cannon CP,
Emanuelsson H, Held C, et al. Ticagrelor ver-
sus clopidogrel in patients with acute coronary
syndromes. N Engl J Med (2009) 361:1045–57.
doi:10.1056/NEJMoa0904327
14. Stevens JW, Simpson E, Harnan S, Squires H,
Meng Y, Thomas S, et al. Systematic review of
the efficacy of cilostazol, naftidrofuryl oxalate and
pentoxifylline for the treatment of intermittent
claudication. Br J Surg (2012) 99:1630–8. doi:10.
1002/bjs.8895
15. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson
BA, Anderson KM, Stoner GL, et al. Effects of
platelet glycoprotein IIb/IIIa receptor blockade
by a chimeric monoclonal antibody (abciximab)
on acute and six-month outcomes after percuta-
neous transluminal coronary angioplasty for acute
myocardial infarction. EPIC investigators. Am J
Cardiol (1996) 77:1045–51. doi:10.1016/S0002-
9149(96)00128-2
16. Stone GW, Maehara A, Witzenbichler B, Godlewski
J, Parise H, Dambrink JH, et al. Intracoro-
nary abciximab and aspiration thrombectomy in
patients with large anterior myocardial infarction:
the INFUSE-AMI randomized trial. JAMA (2012)
307:1817–26. doi:10.1001/jama.2012.421
17. Van’t Hof AW, Ten Berg J, Heestermans T, Dill
T, Funck RC, Van Werkum W, et al. Prehospi-
tal initiation of tirofiban in patients with ST-
elevation myocardial infarction undergoing pri-
mary angioplasty (On-TIME 2): a multicentre,
double-blind, randomised controlled trial. Lancet
(2008) 372:537–46. doi:10.1016/S0140-6736(08)
61235-0
18. O’shea JC, Hafley GE, Greenberg S, Hasselblad
V, Lorenz TJ, Kitt MM, et al. Platelet glyco-
protein IIb/IIIa integrin blockade with eptifi-
batide in coronary stent intervention: the ESPRIT
trial: a randomized controlled trial. JAMA (2001)
285:2468–73. doi:10.1001/jama.285.19.2468
19. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson
A, Hylek E. The pharmacology and management
of the vitamin K antagonists: the Seventh ACCP
Conference on Antithrombotic and Thrombolytic
Therapy.Chest (2004) 126:204S–33S. doi:10.1378/
chest.126.3_suppl.204S
20. Best CH, Bauer G. Heparin and thrombosis: Har-
vey lecture, November 28, 1940. Bull NYAcadMed
(1941) 17:796–817.
21. Bauer G. Thrombosis; early diagnosis and
abortive treatment with heparin. Lancet
(1946) 247:447–54. doi:10.1016/S0140-6736(46)
91429-8
22. Torbicki A, Perrier A, Konstantinides S, Agnelli
G, Galie N, Pruszczyk P, et al. Guidelines on the
diagnosis and management of acute pulmonary
embolism: the Task Force for the Diagnosis
and Management of Acute Pulmonary Embolism
of the European Society of Cardiology (ESC).
Eur Heart J (2008) 29:2276–315. doi:10.1093/
eurheartj/ehn310
23. Holbrook A, Schulman S, Witt DM, Vandvik PO,
Fish J, Kovacs MJ, et al. Evidence-based manage-
ment of anticoagulant therapy: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest (2012)
141:152S–84S. doi:10.1378/chest.11-2295
24. ENOXACAN Study Group. Efficacy and safety of
enoxaparin versus unfractionated heparin for pre-
vention of deep vein thrombosis in elective cancer
surgery: a double-blind randomized multicentre
trial with venographic assessment.Br J Surg (1997)
84:1099–103. doi:10.1046/j.1365-2168.1997.d01-
3882.x
www.frontiersin.org August 2014 | Volume 1 | Article 4 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lang A new view of thrombosis
25. Hamm CW, Bassand JP, Agewall S, Bax J,
Boersma E, Bueno H, et al. ESC Guidelines for
the management of acute coronary syndromes in
patients presenting without persistent ST-segment
elevation: The Task Force for the management
of acute coronary syndromes (ACS) in patients
presenting without persistent ST-segment eleva-
tion of the European Society of Cardiology (ESC).
Eur Heart J (2011) 32:2999–3054. doi:10.1093/
eurheartj/ehr236
26. Task Force M, Montalescot G, Sechtem U, Achen-
bach S,Andreotti F,Arden C, et al. 2013 ESC guide-
lines on the management of stable coronary artery
disease: the Task Force on the management of sta-
ble coronary artery disease of the European Society
of Cardiology. Eur Heart J (2013) 34:2949–3003.
doi:10.1093/eurheartj/eht296
27. Simonneau G, Sors H, Charbonnier B, Page Y,
Laaban JP, Azarian R, et al. A comparison of
low-molecular-weight heparin with unfraction-
ated heparin for acute pulmonary embolism. The
THESEE Study Group. Tinzaparine ou Heparine
Standard: Evaluations dans l’Embolie Pulmonaire.
N Engl J Med (1997) 337:663–9. doi:10.1056/
NEJM199709043371002
28. Fifth Organization to Assess Strategies in Acute
Ischemic Syndromes, Yusuf S, Mehta SR, Chrolavi-
cius S, Afzal R, Pogue J, et al. Comparison of
fondaparinux and enoxaparin in acute coronary
syndromes. N Engl J Med (2006) 354:1464–76.
doi:10.1056/NEJMoa055443
29. Turpie A, Bauer K, Eriksson B, Lassen M, Steering
Committees of the Pentasaccharide Orthopedic
Prophylaxis. Efficacy and safety of fondaparinux in
major orthopedic surgery according to the timing
of its first administration.ThrombHaemost (2003)
90:364–6. doi:10.1267/THRO03020364
30. Lassen MR, Ageno W, Borris LC, Lieberman
JR, Rosencher N, Bandel TJ, et al. Rivaroxaban
versus enoxaparin for thromboprophylaxis after
total knee arthroplasty. N Engl J Med (2008)
358:2776–86. doi:10.1056/NEJMoa076016
31. Patel MR, Mahaffey KW, Garg J, Pan G, Singer
DE, Hacke W, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. NEngl J Med (2011)
365:883–91. doi:10.1056/NEJMoa1009638
32. Mega JL, Braunwald E, Wiviott SD, Bassand
J-P, Bhatt DL, Bode C, et al. Rivaroxaban in
patients with a recent acute coronary syndrome.
N Engl J Med (2012) 366:9–19. doi:10.1056/
NEJMoa1112277
33. Granger CB, Alexander JH, Mcmurray JJ, Lopes
RD, Hylek EM, Hanna M, et al. Apixaban ver-
sus warfarin in patients with atrial fibrillation.
N Engl J Med (2011) 365:981–92. doi:10.1056/
NEJMoa1107039
34. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen
D, Hornick P, et al. Apixaban versus enoxaparin
for thromboprophylaxis after knee replacement
(ADVANCE-2): a randomised double-blind trial.
Lancet (2010) 375:807–15. doi:10.1016/S0140-
6736(09)62125-5
35. Organisation to Assess Strategies for Ischemic
Syndromes (OASIS-2) Investigators. Effects of
recombinant hirudin (lepirudin) compared with
heparin on death, myocardial infarction, refrac-
tory angina, and revascularisation procedures in
patients with acute myocardial ischaemia without
ST elevation: a randomised trial. Lancet (1999)
353:429–38.
36. Stone GW, White HD, Ohman EM, Bertrand ME,
Lincoff AM, Mclaurin BT, et al. Bivalirudin in
patients with acute coronary syndromes under-
going percutaneous coronary intervention: a sub-
group analysis from the Acute Catheterization
and Urgent Intervention Triage strategy (ACU-
ITY) trial. Lancet (2007) 369:907–19. doi:10.1016/
S0140-6736(07)60450-4
37. Wallentin L, Yusuf S, Ezekowitz MD, Alings M,
Flather M, Franzosi MG, et al. Efficacy and safety
of dabigatran compared with warfarin at different
levels of international normalised ratio control for
stroke prevention in atrial fibrillation: an analy-
sis of the RE-LY trial. Lancet (2010) 376:975–83.
doi:10.1016/S0140-6736(10)61194-4
38. Schulman S, Kearon C, Kakkar AK, Schellong S,
Eriksson H, Baanstra D, et al. Extended use of
dabigatran, warfarin, or placebo in venous throm-
boembolism. N Engl J Med (2013) 368:709–18.
doi:10.1056/NEJMoa1113697
39. Schulman S, Kakkar AK, Goldhaber SZ, Schel-
long S, Eriksson H, Mismetti P, et al. Treat-
ment of acute venous thromboembolism with
dabigatran or warfarin and pooled analy-
sis. Circulation (2014) 129:764–72. doi:10.1161/
CIRCULATIONAHA.113.004450
40. Dasararaju R, Singh N, Mehta A. Heparin induced
thrombocytopenia: review. Expert Rev Hema-
tol (2013) 6:419–28. doi:10.1586/17474086.2013.
814446
41. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical
trial of streptokinase and heparin in the treatment
of major pulmonary embolism. Acta Med Scand
(1978) 203:465–70. doi:10.1111/j.0954-6820.1978.
tb14909.x
42. Gruppo Italiano per lo Studio della Streptochi-
nasi nell’Infarto Miocardico (GISSI). Effectiveness
of intravenous thrombolytic treatment in acute
myocardial infarction. Lancet (1986) 1:397–402.
43. The National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study Group. Tissue
plasminogen activator for acute ischemic stroke.
N Engl J Med (1995) 333:1581–7. doi:10.1056/
NEJM199512143332401
44. Weaver WD. Results of the RAPID 1 and RAPID
2 thrombolytic trials in acute myocardial infarc-
tion. Eur Heart J (1996) 17(Suppl E):14–20. doi:
10.1093/eurheartj/17.suppl_E.14
45. Van De Werf F, Adgey J, Ardissino D, Arm-
strong PW, Aylward P, Barbash G, et al. Single-
bolus tenecteplase compared with front-loaded
alteplase in acute myocardial infarction: the
ASSENT-2 double-blind randomised trial. Lancet
(1999) 354:716–22. doi:10.1016/S0140-6736(99)
07403-6
46. Ridker PM, Goldhaber SZ, Danielson E, Rosen-
berg Y, Eby CS, Deitcher SR, et al. Long-term, low-
intensity warfarin therapy for the prevention of
recurrent venous thromboembolism. NEngl J Med
(2003) 348:1425–34. doi:10.1056/NEJMoa035029
47. Romualdi E, Donadini MP, Ageno W. Oral
rivaroxaban after symptomatic venous throm-
boembolism: the continued treatment study
(EINSTEIN-extension study). Expert Rev
Cardiovasc Ther (2011) 9:841–4. doi:10.1586/erc.
11.62
48. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS,
Johnson M, et al. Apixaban for extended treatment
of venous thromboembolism.NEngl JMed (2013)
368:699–708. doi:10.1056/NEJMoa1207541
49. Ridker PM, Danielson E, Fonseca FA, Genest J,
Gotto AM Jr., Kastelein JJ, et al. Rosuvastatin to
prevent vascular events in men and women with
elevated C-reactive protein. N Engl J Med (2008)
359:2195–207. doi:10.1056/NEJMoa0807646
50. Furchgott RF, Zawadzki JV. The obligatory role
of endothelial cells in the relaxation of arterial
smooth muscle by acetylcholine. Nature (1980)
288:373–6. doi:10.1038/288373a0
51. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaud-
huri G. Endothelium-derived relaxing factor pro-
duced and released from artery and vein is nitric
oxide. Proc Natl Acad Sci U S A (1987) 84:9265–9.
doi:10.1073/pnas.84.24.9265
52. Goldstein JL, Brown MS. The LDL receptor. Arte-
rioscler Thromb Vasc Biol (2009) 29:431–8. doi:10.
1161/ATVBAHA.108.179564
53. Brown MS, Goldstein JL. A receptor-mediated
pathway for cholesterol homeostasis. Science
(1986) 232:34–47. doi:10.1126/science.3513311
54. Nemerson Y. A different view of thrombosis. Blood
Coagul Fibrinolysis (2000) 11(Suppl 1):S1–2. doi:
10.1097/00001721-200004001-00001
55. Engelmann B, Massberg S. Thrombosis as
an intravascular effector of innate immunity.
Nat Rev Immunol (2013) 13:34–45. doi:10.1038/
nri3345
56. Borissoff JI, Spronk HM, Ten Cate H. The hemo-
static system as a modulator of atherosclerosis.
N Engl J Med (2011) 364:1746–60. doi:10.1056/
NEJMra1011670
57. Sorensen HT, Horvath-Puho E, Pedersen L, Baron
JA, Prandoni P. Venous thromboembolism and
subsequent hospitalisation due to acute arter-
ial cardiovascular events: a 20-year cohort study.
Lancet (2007) 370:1773–9. doi:10.1016/S0140-
6736(07)61745-0
58. Kucher N, Boekstegers P, Muller OJ, Kupatt
C, Beyer-Westendorf J, Heitzer T, et al. Ran-
domized, controlled trial of ultrasound-
assisted catheter-directed thrombolysis
for acute intermediate-risk pulmonary
embolism. Circulation (2014) 129:479–86.
doi:10.1161/CIRCULATIONAHA.113.005544
59. Sugimura K, Fukumoto Y, Satoh K, Nochioka
K, Miura Y, Aoki T, et al. Percutaneous translu-
minal pulmonary angioplasty markedly improves
pulmonary hemodynamics and long-term prog-
nosis in patients with chronic thromboembolic
pulmonary hypertension. Circ J (2012) 76:485–8.
doi:10.1253/circj.CJ-11-1217
60. Kataoka M, Inami T, Hayashida K, Shimura N,
Ishiguro H, Abe T, et al. Percutaneous translu-
minal pulmonary angioplasty for the treatment
of chronic thromboembolic pulmonary hyper-
tension. Circ Cardiovasc Interv (2012) 5:756–62.
doi:10.1161/circinterventions.112.971390
61. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi
E, Ozaki K, et al. Right ventricular reverse
remodelling after balloon pulmonary angioplasty.
Eur Respir J (2014) 43:1394–402. doi:10.1183/
09031936.00012914
62. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi
H, Ito H,Matsubara H. Refined balloon pulmonary
Frontiers in Cardiovascular Medicine | Thrombosis August 2014 | Volume 1 | Article 4 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lang A new view of thrombosis
angioplasty for inoperable patients with chronic
thromboembolic pulmonary hypertension. Circ
Cardiovasc Interv (2012) 5:748–55. doi:10.1161/
circinterventions.112.971077
Conflict of Interest Statement: Irene M. Lang has
relationships with drug companies including AOPOr-
phan Pharmaceuticals, Abbott, Actelion, Astra-Zeneca,
Bayer-Schering, Cordis, Glaxo Smith Kline, Medtronic,
Novartis, Pfizer, Servier, and United Therapeutics. In
addition to being investigator in trials involving these
companies, relationships include consultancy service,
research grants, and membership of scientific advisory
boards.
Received: 24 June 2014; accepted: 04 August 2014;
published online: 18 August 2014.
Citation: Lang IM (2014) Thrombosis – besieged but
poorly understood. Front. Cardiovasc. Med. 1:4. doi:
10.3389/fcvm.2014.00004
This article was submitted to Thrombosis, a section of the
journal Frontiers in Cardiovascular Medicine.
Copyright © 2014 Lang . This is an open-access article
distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with
these terms.
www.frontiersin.org August 2014 | Volume 1 | Article 4 | 7
